MK-0686 is a bradykinin B1 receptor antagonist. It exhibits suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation. References: Tang C, Carr BA, Poignant F, Ma B, Polsky-Fisher SL, Kuo Y, Strong-Basalyga K, Norcross A, Richards K, Eisenhandler R, Carlini EJ, Di Marco CN, Kuduk SD, Yu NX, Raab CE, Rushmore T, Frederick CB, Bock MG, Prueksaritanont T. CYP2C75-involved autoinduction of metabolism in rhesus monkeys of methyl 3-chloro-3'-fluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)a mino]ethyl}-1,1'-biphenyl-2-carboxylate (MK-0686), a bradykinin B1 receptor antagonist. J Pharmacol Exp Ther. 2008 Jun;325(3):935-46. doi: 10.1124/jpet.107.136044. Epub 2008 Feb 29. PubMed PMID: 18310472. 2: Kuduk SD, Di Marco CN, Chang RK, Wood MR, Schirripa KM, Kim JJ, Wai JM, DiPardo RM, Murphy KL, Ransom RW, Harrell CM, Reiss DR, Holahan MA, Cook J, Hess JF, Sain N, Urban MO, Tang C, Prueksaritanont T, Pettibone DJ, Bock MG. Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists. J Med Chem. 2007 Jan 25;50(2):272-82. PubMed PMID: 17228869.

纯度：≥98%

CAS：578727-68-1